bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(2.40) by 73.33 percent. This is a 87.45 percent increase over losses of $(5.10) per share from the same period last year. The company reported quarterly sales of $1.511 million which beat the analyst consensus estimate of $1.483 million by 1.89 percent. This is a 19.07 percent increase over sales of $1.269 million the same period last year.